Cure51 launches NHS-approved study with Cambridge University Hospitals and seven other leading UK oncology institutions to unlock cancer survival secrets
- Pioneering Rosalind study aims to transform cancer treatment with insights from ‘super-responder’ patients
- Tumor samples from over 1,000 cancer survivors across three aggressive types will be analyzed for genetics and biomarkers
- Findings will enrich Cure51’s multi-omics database to advance new biology and precision medicine tools
Paris, France, 18 November 2024 – Cure51, a techbio company seeking to unlock the biological mechanisms responsible for exceptional cancer survivors patients, today announces the UK launch of the Rosalind study, a groundbreaking initiative already underway in other parts of Europe. The UK phase, in collaboration with Cambridge University Hospitals and seven other top UK-based institutions was recently approved by the NHS Health Research Authority (HRA) and aims to decode the biological factors behind long-term cancer survival and unlock insights that could pave the way for more effective cancer treatments.
